Hans Bigalke

Carl Neuberg Str. 1
Hannover, NI 30625, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Therapeutic botulinum toxin preparations: an update.

Therapeutic botulinum toxin preparations: an update.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: October 09, 2025

Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin.

Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin.

Journal: Journal of neurology

Published: August 16, 2022

Botulinum toxin antibody titres: measurement, interpretation, and practical recommendations.

Botulinum toxin antibody titres: measurement, interpretation, and practical recommendations.

Journal: Journal of neurology

Published: August 12, 2022

The immunology of botulinum toxin therapy: A brief summary.

The immunology of botulinum toxin therapy: A brief summary.

Journal: Toxicology

Published: July 21, 2022

Long-term adherence and response to botulinum toxin in different indications.

Long-term adherence and response to botulinum toxin in different indications.

Journal: Annals of clinical and translational neurology

Published: August 19, 2020

Author response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.

Author response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.

Journal: Neurology

Published: October 23, 2019

Author response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.

Author response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.

Journal: Neurology

Published: October 23, 2019

Comparing lanbotulinumtoxinA (Hengli®) with onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in the mouse hemidiaphragm assay.

Comparing lanbotulinumtoxinA (Hengli®) with onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in the mouse hemidiaphragm assay.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: August 13, 2019

The role of human serum albumin and neurotoxin associated proteins in the formulation of BoNT/A products.

The role of human serum albumin and neurotoxin associated proteins in the formulation of BoNT/A products.

Journal: Toxicon : official journal of the International Society on Toxinology

Published: March 25, 2019

Botulinum toxin type D blocks autonomic cholinergic synapses in humans: discussion of a potential therapeutic use.

Botulinum toxin type D blocks autonomic cholinergic synapses in humans: discussion of a potential therapeutic use.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: November 05, 2018

Do complexing proteins provide mechanical protection for botulinum neurotoxins?

Do complexing proteins provide mechanical protection for botulinum neurotoxins?

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: November 01, 2018

Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients.

Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients.

Journal: Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology

Published: September 21, 2018

Showing 1-12 of 31

Last Updated: 09/26/2026